|Global tuberculosis drug development pipeline: the need and the reality|
Z Ma, C Lienhardt, H McIlleron, AJ Nunn, X Wang
The Lancet 375 (9731), 2100-2109, 2010
|The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis|
K Dheda, T Gumbo, G Maartens, KE Dooley, R McNerney, M Murray, ...
The lancet Respiratory medicine 5 (4), 291-360, 2017
|High-dose rifapentine with moxifloxacin for pulmonary tuberculosis|
A Jindani, TS Harrison, AJ Nunn, PPJ Phillips, GJ Churchyard, ...
N Engl J Med 371, 1599-1608, 2014
|Serum drug concentrations predictive of pulmonary tuberculosis outcomes|
JG Pasipanodya, H McIlleron, A Burger, PA Wash, P Smith, T Gumbo
The Journal of infectious diseases 208 (9), 1464-1473, 2013
|Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome|
H McIlleron, G Meintjes, WJ Burman, G Maartens
The Journal of infectious diseases 196 (Supplement_1), S63-S75, 2007
|Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients|
H McIlleron, P Wash, A Burger, J Norman, PI Folb, P Smith
Antimicrobial agents and chemotherapy 50 (4), 1170-1177, 2006
|Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears|
AH Diacon, RF Patientia, A Venter, PD Van Helden, PJ Smith, H McIlleron, ...
Antimicrobial agents and chemotherapy 51 (8), 2994-2996, 2007
|Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption|
JJ Wilkins, RM Savic, MO Karlsson, G Langdon, H McIlleron, G Pillai, ...
Antimicrobial agents and chemotherapy 52 (6), 2138-2148, 2008
|Research capacity. Enabling the genomic revolution in Africa|
C Rotimi, A Abayomi, A Abimiku, VM Adabayeri, C Adebamowo, ...
|Enabling the genomic revolution in Africa|
Science 344 (6190), 1346-1348, 2014
|Isoniazid plasma concentrations in a cohort of South African children with tuberculosis: implications for international pediatric dosing guidelines|
H McIlleron, M Willemse, CJ Werely, GD Hussey, HS Schaaf, PJ Smith, ...
Clinical Infectious Diseases 48 (11), 1547-1553, 2009
|Effect of rifampicin on lopinavir pharmacokinetics in HIV-infected children with tuberculosis|
Y Ren, JJC Nuttall, C Egbers, BS Eley, TM Meyers, PJ Smith, G Maartens, ...
JAIDS Journal of Acquired Immune Deficiency Syndromes 47 (5), 566-569, 2008
|The SLCO1B1 rs4149032 Polymorphism Is Highly Prevalent in South Africans and Is Associated with Reduced Rifampin Concentrations: Dosing Implications|
E Chigutsa, ME Visser, EC Swart, P Denti, S Pushpakom, D Egan, ...
Antimicrobial agents and chemotherapy 55 (9), 4122-4127, 2011
|The early bactericidal activities of rifampin and rifapentine in pulmonary tuberculosis|
FA Sirgel, PB Fourie, PR Donald, N Padayatchi, R Rustomjee, J Levin, ...
American journal of respiratory and critical care medicine 172 (1), 128-135, 2005
|Low lopinavir plasma or hair concentrations explain second line protease inhibitor failures in a resource-limited setting|
GU Van Zyl, TE Van Mens, H McIlleron, M Zeier, JB Nachega, E Decloedt, ...
Journal of acquired immune deficiency syndromes (1999) 56 (4), 333, 2011
|Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosis|
K Cohen, G van Cutsem, A Boulle, H McIlleron, E Goemaere, PJ Smith, ...
Journal of antimicrobial chemotherapy 61 (2), 389-393, 2008
|Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis|
E Chigutsa, JG Pasipanodya, ME Visser, PD Van Helden, PJ Smith, ...
Antimicrobial agents and chemotherapy 59 (1), 38-45, 2015
|Effect of rifampicin-based antitubercular therapy and the cytochrome P450 2B6 516G> T polymorphism on efavirenz concentrations in adults in South Africa|
K Cohen, A Grant, C Dandara, H McIlleron, L Pemba, K Fielding, ...
Antivir Ther 14 (5), 687-95, 2009
|Variability in the population pharmacokinetics of isoniazid in South African tuberculosis patients|
JJ Wilkins, G Langdon, H McIlleron, G Pillai, PJ Smith, USH Simonsson
British journal of clinical pharmacology 72 (1), 51-62, 2011
|Reduced antituberculosis drug concentrations in HIV-infected patients who are men or have low weight: implications for international dosing guidelines|
H McIlleron, R Rustomjee, M Vahedi, T Mthiyane, P Denti, C Connolly, ...
Antimicrobial agents and chemotherapy 56 (6), 3232-3238, 2012